Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$124.2m

Nuvectis Pharma Future Growth

Future criteria checks 0/6

Nuvectis Pharma is forecast to grow earnings and revenue by 20.4% and 66.8% per annum respectively while EPS is expected to grow by 23.3% per annum.

Key information

20.4%

Earnings growth rate

23.3%

EPS growth rate

Biotechs earnings growth23.2%
Revenue growth rate66.8%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Apr 2024

Recent future growth updates

No updates

Recent updates

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

Jan 06
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Oct 03
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Jan 31
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Sep 28

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Aug 05

Nuvectis Pharma declines 13%, announces $15.9M private placement

Jul 27

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

May 04
We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Earnings and Revenue Growth Forecasts

NasdaqCM:NVCT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262-39N/AN/A3
12/31/2025N/A-34N/AN/A3
12/31/2024N/A-29N/AN/A3
12/31/2023N/A-22-16-16N/A
9/30/2023N/A-22-16-16N/A
6/30/2023N/A-22-17-17N/A
12/31/2022N/A-19-14-14N/A
9/30/2022N/A-15-11-11N/A
6/30/2022N/A-13-11-11N/A
3/31/2022N/A-16-13-13N/A
12/31/2021N/A-13-10-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NVCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NVCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NVCT is forecast to have no revenue next year.

High Growth Revenue: NVCT is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NVCT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.